Literature DB >> 12496449

Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice.

Norma Ostlie1, Monica Milani, Wei Wang, David Okita, Bianca M Conti-Fine.   

Abstract

Myasthenia gravis (MG) is a T cell-dependent, Ab-mediated autoimmune disease. Ab against muscle acetylcholine receptor (AChR) cause the muscular weakness that characterizes MG and its animal model, experimental MG (EMG). EMG is induced in C57BL6 (B6) mice by three injections of Torpedo AChR (TAChR) in adjuvant. B6 mice develop anti-TAChR Ab that cross-react with mouse muscle AChR, but their CD4+ T cells do not cross-react with mouse AChR sequences. Moreover, murine EMG is not self-maintaining as is human MG, and it has limited duration. Several studies suggest that IL-4 has a protecting function in EMG. Here we show that B6 mice genetically deficient in IL-4 (IL-4-/-) develop long-lasting muscle weakness after a single immunization with TAChR. They develop chronic self-reactive Ab, and their CD4+ T cells respond not only to the TAChR and TAChR subunit peptides, but also to several mouse AChR subunit peptides. These results suggest that in B6 mice, regulatory mechanisms that involve IL-4 contribute to preventing the development of a chronic Ab-mediated autoimmune response to the AChR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496449     DOI: 10.4049/jimmunol.170.1.604

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 2.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

3.  C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.

Authors:  Wei Wang; Monica Milani; Norma Ostlie; David Okita; Rajeev K Agarwal; Rachel R Caspi; Rachel Caspi; Bianca M Conti-Fine
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

4.  Serum cytokine and chemokine profiles in patients with myasthenia gravis.

Authors:  A Uzawa; N Kawaguchi; K Himuro; T Kanai; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

5.  TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm.

Authors:  Y Nagayama; O Saitoh; S M McLachlan; B Rapoport; H Kano; Y Kumazawa
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

6.  Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis.

Authors:  Chang-Suk Chae; Ho-Keun Kwon; Ji-Sun Hwang; Jung-Eun Kim; Sin-Hyeog Im
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

7.  IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population.

Authors:  Ping Jiang; Yao-Xian Yue; Yu Hong; Yanchen Xie; Xiang Gao; Chuan-Kai Gu; Hong-Jun Hao; Yue Qin; Xiao-Jun Ding; Min Song; Hai-Feng Li; Xu Zhang
Journal:  Front Neurol       Date:  2018-07-10       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.